Dr. Prelaj Arsela
Doctor
Contacts
- Mail: arsela.prelaj@istitutotumori.mi.it
Specialty / Department
- Medical Oncology
She currently works as a Medical Oncologist with both a strong interest and commitment to translational research at the Fondazione IRCCS Istituto Nazionale dei Tumori of Milan. In the last five years she has focused her research on Thoracic Malignancies, especially in NSCLC patients treated with immunotherapy and target therapy, being sub and principal investigator of many clinical studies/trials and closely involved in the coordination of various national and international grant applications on this topic. She is the prinicipal investigator of the I3LUNG and Apollo11 projects.
- Mail: arsela.prelaj@istitutotumori.mi.it
To book an appointment, you can use the online service (click here), contact the CUP on +39 0223901, or visit the Foundation’s reception desks in person.
Medical Oncology 1
Thoracic Oncology Unit
A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomi
APOLLO 11: consortium in advanced lung cancer patients treated with innovative therapies; integration of real world data and translational research
I3LUNG - Integrative science, Intelligent data platform for Individualized Lung cancer care with Immunotherapy
SHAIPED
BuonMarrow: Bone Marrow-on-Chip as smart sensor of lung cancer relapse
EPIGENETICS IN SCLC TO EARLY DETECT TREATMENT RESISTANCE AND DISCOVERY NEW DRUGGABLE PATHWAYS
Last update: 04/06/2026